|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Retrospective Study of the Efficacy and Safety of Hema-Plus (Recombinant Human Erythropoietin Alfa) in Patients with Chronic Kidney Disease who continuously used Hema-Plus at Siriraj Hospital
A Prospective Study on Efficacy and Safety of Filgrastim (Leuco-Plus 300) for Prevention of Chemotherapy Induced Neutropenia in Patients with Diffuse Large B-Cell Lymphoma
A Study to Observe Pure Red Cell Aplasia (PRCA) Occurrence in Patients with Chronic Kidney Disease Who Used Hema-Plus (Recombinant Human Erythropoietin Alfa) at Ramathibodi Hospital
100 Clinical Results associated with Apexcela Co., Ltd.
0 Patents (Medical) associated with Apexcela Co., Ltd.
100 Deals associated with Apexcela Co., Ltd.
100 Translational Medicine associated with Apexcela Co., Ltd.